{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:47:36Z","timestamp":1782510456508,"version":"3.54.5"},"reference-count":171,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000948","name":"Pfizer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.diagmicrobio.2019.01.020","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T00:53:01Z","timestamp":1549327981000},"page":"413-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Antimicrobial treatment challenges in the era of carbapenem resistance"],"prefix":"10.1016","volume":"94","author":[{"given":"Anna Maria","family":"Peri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Potoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick N.A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elda","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.diagmicrobio.2014.06.010","article-title":"Microbiological features of KPC-producing Enterobacter isolates identified in a U.S. hospital system","volume":"80","author":"Ahn","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijantimicag.2011.09.012","article-title":"In vitro activity of avibactam (NXL104) in combination with \u03b2-lactams against gram-negative bacteria, including OXA-48 \u03b2-lactamase-producing Klebsiella pneumoniae","volume":"39","author":"Akta\u015f","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0015","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.45.30062","article-title":"Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts in 38 countries, May 2015","volume":"20","author":"Albiger","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13613-016-0211-z","article-title":"Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock","volume":"6","author":"Allou","year":"2016","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0025","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1128\/AAC.47.5.1643-1646.2003","article-title":"Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum \u03b2-lactamases: report from the ARREST program","volume":"47","author":"Ambrose","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0030","first-page":"71","article-title":"Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin","volume":"39","author":"Apisarnthanarak","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0035","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jhin.2017.11.014","article-title":"Rapid emergence of colistin resistance and its impact on fatality among healthcare-associated infections","volume":"98","author":"Ayd\u0131n","year":"2018","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0040","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/13543784.2014.965253","article-title":"Eravacycline for the treatment of intra-abdominal infections","volume":"23","author":"Bassetti","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jac\/dkm509","article-title":"Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections","volume":"61","author":"Bassetti","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0050","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1128\/AAC.02365-12","article-title":"Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0055","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40121-015-0093-7","article-title":"Optimizing polymyxin combinations against resistant gram-negative bacteria","volume":"4","author":"Bergen","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0065","series-title":"Pharmacokinetic-pharmacodynamic basis for CLSI carbapenems susceptibility breakpoint changes, abstr A1-1382","author":"Bhavnani","year":"2010"},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0070","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1093\/ofid\/ofy209.170","article-title":"Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics\u2013Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data","volume":"5","author":"Bhavnani","year":"2018","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0075","article-title":"Emergence of ceftazidime\/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate","volume":"23","author":"Both","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0080","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/jac\/dku189","article-title":"Tigecycline in treatment of multidrug-resistant gram-negative bacillus urinary tract infections: a systematic review","volume":"69","author":"Brust","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0085","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1128\/AAC.01420-10","article-title":"Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae","volume":"55","author":"Bulik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0090","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0095","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/cid\/ciu706","article-title":"Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options","volume":"59","author":"Castanheira","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0100","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1128\/AAC.00163-15","article-title":"Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 \u2013 2013) and characterization of B-lactamase producing strains","volume":"59","author":"Castanheira","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0105","author":"Centers for Disease Control & Prevention (CDC)"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0110","author":"Centers for Disease Control & Prevention (CDC): Health Alert Network"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0885066610377975","article-title":"Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"25","author":"Chan","year":"2010","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0120","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1128\/AAC.01949-13","article-title":"Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes","volume":"58","author":"Clancy","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0125","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1021\/jm201467r","article-title":"Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy","volume":"55","author":"Clark","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0130","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0135","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0145","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb9000","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0150","doi-asserted-by":"crossref","first-page":"S532","DOI":"10.1093\/ofid\/ofx163.1385","article-title":"Plazomicin vs. meropenem for complicated urinary tract infection (cUTI) and acute pyelonephritis (AP): diagnosis-specific results from the Phase 3 EPIC Study","volume":"4","author":"Cloutier","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0155","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00794-17","article-title":"Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae","volume":"61","author":"Cojutti","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0160","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01989-17","article-title":"A multicenter, randomized, double-blind, Phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis","volume":"62","author":"Connolly","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0170","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0175","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0180","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0185","unstructured":"Ditch K, Newman J, Izmailyan S, Fyfe C, Tsai L. Microbiological Efficacy of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including MDR Isolates: A Pooled Analysis from IGNITE1 and IGNITE4, Two Phase 3 Trials of Complicated Intra-Abdominal Infection. Presented at ASM Microbe 2018, Atlanta, GA"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0190","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijantimicag.2011.10.012","article-title":"Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli","volume":"39","author":"Docobo-Perez","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0195","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.02190-12","article-title":"Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum \u03b2-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model","volume":"57","author":"Docobo-P\u00e9rez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0200","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.idc.2016.02.011","article-title":"Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases","volume":"30","author":"Doi","year":"2016","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0205","author":"Doribax drug label"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0210","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0215","author":"EMA"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0220","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1128\/AAC.00556-09","article-title":"ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates","volume":"53","author":"Endimiani","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0225","series-title":"Emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae \u2013 12 June 2018","author":"European Centre for Disease Prevention and Control","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0230","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1469-0691.2006.01559.x","article-title":"Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin\u2013meropenem combination therapy for multidrug-resistant gram-negative bacterial infections","volume":"12","author":"Falagas","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0235","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10096-007-0456-4","article-title":"Antimicrobial susceptibility of multi-drug resistant gram-negative bacteria to fosfomycin","volume":"27","author":"Falagas","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0240","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0245","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijantimicag.2009.10.005","article-title":"Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0250","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.01222-13","article-title":"Antibiotic treatment of infections due to carbapenem-resistant carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence","volume":"58","author":"Falagas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0255","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/jac\/dkx049","article-title":"Activity of cefiderocol (S-649266) against carbapenem-resistant gram-negative bacteria collected from inpatients in Greek hospitals","volume":"72","author":"Falagas","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0260","author":"FDA Briefing Document"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0265","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1179\/1973947813Y.0000000145","article-title":"Avibactam reverts the ceftazidime MIC90 of European gram-negative bacterial clinical isolates to the epidemiological cut-off value","volume":"26","author":"Flamm","year":"2014","journal-title":"J Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0770","series-title":"US Department of Health andHumanServices","article-title":"Guidance for industry. Antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. Center for Drug Evaluation and Research, Food and Drug Administration","author":"Food and Drug Administration","year":"2013"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2017.09.017","article-title":"In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates","volume":"65","author":"Gaibani","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0275","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1179\/1973947812Y.0000000015","article-title":"Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece","volume":"24","author":"Galani","year":"2012","journal-title":"J Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0280","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/374337","article-title":"Treatment of multidrug-resistant Acinetobacter baumannii ventilator associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP","volume":"36","author":"Garnacho-Montero","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0285","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00134-015-4079-4","article-title":"Task force on management and prevention of Acinetobacter baumannii infections in the ICU","volume":"41","author":"Garnacho-Montero","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0290","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0295","doi-asserted-by":"crossref","first-page":"e9961","DOI":"10.1097\/MD.0000000000009961","article-title":"High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study","volume":"97","author":"Geng","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0300","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijantimicag.2017.08.019","article-title":"Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection","volume":"51","author":"Giannella","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0305","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02101-17","article-title":"Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-Harboring Klebsiella pneumoniae sequence type 307 isolates","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0310","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1093\/cid\/ciu593","article-title":"Bad bugs need old drugs: a stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections","volume":"59","author":"Goff","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0315","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1128\/AAC.03007-15","article-title":"Combination regimens for treatment of Carbapenem-resistant Klebsiella pneumoniae bloodstream infections","volume":"60","author":"Gomez-Simmonds","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0320","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/jac\/dku432","article-title":"Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae","volume":"70","author":"Gonzalez-Padilla","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0325","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-016-0636-6","article-title":"Intravenous minocycline: A review in Acinetobacter infections","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0330","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/dkp411","article-title":"Bacteraemia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome","volume":"65","author":"Gudiol","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0335","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A multinational, preregistered cohort study of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-\u03b2-lactamase- producing Enterobacteriaceae","volume":"60","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0340","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0345","article-title":"In Vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae","volume":"62","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0350","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jac\/dkt056","article-title":"Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs","volume":"68","author":"Hagihara","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0355","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13756-015-0055-6","article-title":"Comparable outcomes for \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae","volume":"4","author":"Harris","year":"2015","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0360","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: A randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0365","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkq108","article-title":"Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug resistant infection","volume":"65","author":"Hirsch","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0370","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/jac\/dkw053","article-title":"Efficacy of ceftolozane\/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTI) caused by levofloxacin-resistant pathogens: results from the cUTI trial","volume":"71","author":"Huntington","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0375","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s00134-007-0675-2","article-title":"Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case\u2013control study","volume":"33","author":"Kallel","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0380","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1128\/AAC.01450-09","article-title":"Worldwide experience with the use of doripenem against extended-spectrum-\u03b2-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies","volume":"54","author":"Kaniga","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0385","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/jac\/dks270","article-title":"Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases","volume":"67","author":"Karageorgopoulos","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0390","doi-asserted-by":"crossref","unstructured":"Kaye K, Vazquez J, Mathers A, et al. Clinical outcomes of serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) in TANGO II, a phase 3, randomized, multi-national, open-label trial of meropenem-vaborbactam (M-V) versus best available therapy (BAT). Presented at ID Week 2017, San Diego, CA","DOI":"10.1093\/ofid\/ofx163.1392"},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0395","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1093\/ofid\/ofx163.221","article-title":"Minocycline in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae","volume":"4","author":"Khatri","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0400","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0405","doi-asserted-by":"crossref","first-page":"R218","DOI":"10.1186\/cc11862","article-title":"A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia","volume":"16","author":"Kollef","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0410","doi-asserted-by":"crossref","first-page":"O117","DOI":"10.1111\/1469-0691.12341","article-title":"Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-Centre study on clinical outcome and therapeutic options","volume":"20","author":"Kontopidou","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0415","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.ijantimicag.2017.01.018","article-title":"Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime\/avibactam: a retrospective study with molecular strain characterisation","volume":"49","author":"Krapp","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0420","doi-asserted-by":"crossref","first-page":"S726","DOI":"10.1093\/ofid\/ofy210.2083","article-title":"Impact of USCAST Proposed Breakpoint Changes to Aminoglycosides, Cyclines, and Levofloxacin on Carbapenem-Resistant Enterobacteriaceae at a US Tertiary Referral Academic Medical Center","volume":"5","author":"Kulengowski","year":"2018","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0425","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-017-0153-2","article-title":"Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: A review","volume":"6","author":"Lashinsky","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0430","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1128\/AAC.00703-13","article-title":"Synergistic activity of colistin and rifampin combination against multi-drug resistant Acinetobacter baumanni in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Lee","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0435","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","article-title":"Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections","volume":"6","author":"Li","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0440","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1086\/379611","article-title":"Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa","volume":"37","author":"Linden","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0445","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0450","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","article-title":"Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study","volume":"16","author":"Liu","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0455","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0460","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0465","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkx438","article-title":"Activity of ceftazidime\/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16","volume":"73","author":"Livermore","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0470","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0475","article-title":"Minocycline (MINO) Activity Is Enhanced by Polymyxin B (PmB) in TetB Containing Isolates of Acinetobacter baumannii (ACB), Including Those Resistant to PmB","volume":"3","author":"Lomovskaya","year":"2016","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0480","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: spectrum of \u03b2-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0485","article-title":"Assessment of MIC increases with meropenem-vaborbactam and ceftazidime-avibactam in TANGO II (a Phase 3 study of the treatment of CRE infections)","volume":"4","author":"Lomovskaya","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0490","doi-asserted-by":"crossref","first-page":"e00406","DOI":"10.1128\/AAC.00406-17","article-title":"Mortality associated with bacteremia due to colistin-resistant Klebsiella pneumoniae with high-level meropenem resistance: importance of combination therapy without colistin and carbapenems","volume":"61","author":"Machuca","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0495","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/mdr.2016.0293","article-title":"Activity of ceftazidime-avibactam against clinical isolates of Klebsiella pneumoniae, including KPC-carrying isolates, endemic to new York City","volume":"24","author":"Manning","year":"2018","journal-title":"Microb Drug Resist"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0500","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0505","doi-asserted-by":"crossref","first-page":"S531","DOI":"10.1093\/ofid\/ofx163.1383","article-title":"Improved outcomes with Plazomicin (PLZ) compared with Colistin (CST) in patients with bloodstream infections (BSI) caused by Carbapenem-resistant Enterobacteriaceae (CRE): results from the CARE study","volume":"4","author":"McKinnell","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0510","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1469-0691.2009.02921.x","article-title":"Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation","volume":"16","author":"Michalopoulos","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0515","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1128\/AAC.06426-11","article-title":"Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"42","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0520","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.42.20939","article-title":"Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014","volume":"19","author":"Monaco","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0525","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of Ceftolozane\/Tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0530","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/cid\/civ964","article-title":"Updated US and European dose recommendations for intravenous Colistin: how do they perform?","volume":"62","author":"Nation","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0535","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/21505594.2016.1221021","article-title":"Pharmacodynamic and pharmacokinetic considerations in the treatment of critically ill patients infected with carbapenem-resistant Enterobacteriaceae","volume":"8","author":"Neuner","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0540","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1128\/AAC.00402-12","article-title":"Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms","volume":"56","author":"Neuner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0545","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijantimicag.2015.11.011","article-title":"Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis","volume":"47","author":"Ni","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0550","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijantimicag.2011.08.018","article-title":"Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems. A review of the evidence","volume":"39","author":"Nicolau","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"51\u201352","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0555","first-page":"1051","article-title":"New Delhi metallo-\u03b2-lactamase-producing Escherichia coli associated with endoscopic retrograde cholangiopancreatography \u2013 Illinois, 2013. Centers for Disease Control and Prevention (CDC)","volume":"62","author":"Notes from the Field","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0560","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s12879-015-1297-x","article-title":"Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data","volume":"15","author":"Oikonomou","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0565","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cmi.2015.09.014","article-title":"Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae","volume":"22","author":"Oliva","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0570","article-title":"Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens","volume":"6","author":"Ortiz","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0575","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cix606","article-title":"Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: results from the INCREMENT cohort","volume":"65","author":"Palacios-Baena","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0580","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1086\/504476","article-title":"The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species","volume":"43","author":"Paterson","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0585","first-page":"91","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0590","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/cir793","article-title":"Can we really use \u03b2-lactam\/\u03b2-lactam inhibitor combinations for the treatment of infections caused by extended- spectrum \u03b2 -lactamase-producing bacteria?","volume":"54","author":"P\u00e9rez","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0595","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1517\/14656566.2016.1145658","article-title":"Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply \u201cprecision medicine\u201d to antimicrobial chemotherapy?","volume":"17","author":"Perez","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0600","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1128\/AAC.01361-08","article-title":"Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria","volume":"53","author":"Plachouras","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0605","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1093\/cid\/ciu542","article-title":"Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention","author":"Pollack","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0610","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","article-title":"Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing gram-negative bacteria","volume":"43","author":"Pontikis","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0615","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2217\/fmb.14.58","article-title":"Current and future treatment options for infections caused by multidrug-resistant gram-negative pathogens","volume":"9","author":"Poulakou","year":"2014","journal-title":"Future Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0620","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijantimicag.2010.10.031","article-title":"Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay","volume":"37","author":"Pournaras","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0625","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1128\/AAC.06268-11","article-title":"Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens","volume":"56","author":"Qureshi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0630","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0635","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jgar.2014.03.002","article-title":"In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa-Middle East countries: TEST 2007-2012","volume":"2","author":"Renteria","year":"2014","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0640","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/21505594.2016.1255381","article-title":"Screening for carbapenem-resistant Enterobacteriaceae: who, when, and how?","volume":"8","author":"Richter","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0645","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s10096-017-3008-6","article-title":"Impact of antimicrobial stewardship and rapid microarray testing on patients with gram-negative bacteremia","volume":"36","author":"Rivard","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0650","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ijantimicag.2015.07.021","article-title":"In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains","volume":"46","author":"Rodr\u00edguez-Avial","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0655","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0660","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0213-005X(14)70174-0","article-title":"Treatment of infections caused by carbapenemase-producing Enterobacteriaceae","volume":"32","author":"Rodr\u00edguez-Ba\u00f1o","year":"2014","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"S1","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0665","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1093\/ofid\/ofw172.1599","article-title":"Clinical experience with ceftolozane\/tazobactam at a large academic medical center","volume":"3","author":"Sacha","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0670","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2015.06.011","article-title":"Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013)","volume":"83","author":"Sader","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0675","first-page":"890","article-title":"In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases","volume":"42","author":"Santimaleeworagun","year":"2011","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0680","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1128\/AAC.00387-11","article-title":"Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine","volume":"55","author":"Satlin","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0685","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02349-16","article-title":"Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States","volume":"61","author":"Satlin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0690","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/dku351","article-title":"\u03b2-Lactam\/\u03b2-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials","volume":"70","author":"Shiber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0695","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1128\/AAC.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum \u03b2-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0700","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"61(8)","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0705","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"25","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0710","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance Due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2019.01.020_bb0715","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0720","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Colistin versus Colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections: a preliminary study","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0725","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of Eravacycline vs Ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with Eravacycline (IGNITE 1) trial: A randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0730","doi-asserted-by":"crossref","DOI":"10.2807\/ese.15.46.19716-en","article-title":"European NDM-1 survey participants New Delhi metallo-\u03b2-lactamase-1-producing Enterobacteriaceae: emergence and response in Europe","volume":"15","author":"Struelens","year":"2010","journal-title":"Euro Surveill"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0735","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01694-17","article-title":"Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae","volume":"61","author":"Sun","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0740","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","article-title":"In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0745","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0750","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1060028014556652","article-title":"\u03b2-Lactam\/\u03b2-lactamase inhibitor combinations: from then to now","volume":"49","author":"Toussaint","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0755","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0760","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0765","first-page":"61(8)","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by KPC-producing Klebsiella pneumoniae","volume":"25","author":"Tumbarello","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0775","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.02636-14","article-title":"Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network","volume":"58","author":"van Duin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0780","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jac\/dku495","article-title":"Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae","volume":"70","author":"van Duin","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0785","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0790","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0795","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2016.04.014","article-title":"Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum \u03b2-lactamase urinary tract infections","volume":"48","author":"Veve","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0800","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/JCM.00376-16","article-title":"Clinical impact of laboratory implementation of verigene BC-GN microarray-based assay for detection of gram-negative bacteria in positive blood cultures","volume":"54","author":"Walker","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0805","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1128\/AAC.01696-10","article-title":"In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study)","volume":"55","author":"Walkty","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0810","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1099\/jmm.0.008094-0","article-title":"Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated \u03b2-lactamase production and OmpK36 porin deficiency","volume":"58","author":"Wang","year":"2009","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0815","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.00708-13","article-title":"Efficacy of humanized carbapenem exposures against New Delhi metallo-\u03b2-lactamase (NDM-1)-producing Enterobacteriaceae in a murine infection model","volume":"57","author":"Wiskirchen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0820","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/AAC.00734-08","article-title":"Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4","volume":"53","author":"Wolter","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0825","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/21505594.2016.1188234","article-title":"Leveraging antimicrobial stewardship into improving rates of carbapenem-resistant Enterobacteriaceae","volume":"8","author":"Wong","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0830","article-title":"Clinical outcomes with alternative dosing strategies for piperacillin\/tazobactam: a systematic review and meta-analysis","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0835","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1097\/MJT.0b013e3182a32df3","article-title":"Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam","volume":"23","author":"Zalts","year":"2016","journal-title":"Am J Ther"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0840","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/14787210.2017.1316193","article-title":"Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility","volume":"15","author":"Zavascki","year":"2017","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0845","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijantimicag.2013.04.021","article-title":"Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic\/pharmacodynamic analysis using Monte Carlo simulation","volume":"42","author":"Zazo","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0850","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.diagmicrobio.2017.12.013","article-title":"In vitro activity of eravacycline against 2213 gram-negative and 2424 gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015","volume":"91","author":"Zhanel","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.020_bb0855","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem resistant bacteria: systematic review and meta-analysis","volume":"72","author":"Zusman","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319301099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319301099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:52:17Z","timestamp":1760003537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889319301099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":171,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0732889319301099"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.01.020","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial treatment challenges in the era of carbapenem resistance","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}